A Non-Interventional Study Observing Short-Term Progression in GA
Research type
Research Study
Full title
A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
IRAS ID
360808
Contact name
Paulo Eduardo Stanga
Contact email
Sponsor organisation
Complement Therapeutics Ltd.
Duration of Study in the UK
1 years, 5 months, 1 days
Research summary
Age-related macular degeneration (AMD) is a chronic and progressive degenerative disease of the macula, the central part of the retina. It affects approximately 196 million people worldwide and accounts for 8.7% of all blind registrations. There are currently no approved therapies for GA in Europe.
This is a non-interventional, observational study, funded by Complement Therapeutics Ltd. to assess the progression of Geographic atrophy (GA) secondary to age-related macular degeneration (AMD) in participants aged ≥55 years. The purpose of this study is to observe and gather information from patients with GA secondary to AMD in order to allow for quantification of structural and functional parameters for the progression of GA, and to investigate whether there is a correlation to genetic, serological, or lifestyle factors.
Approximately 75 participants, aged ≥55 years, will be enrolled in this study across 15 centers globally. The study will consist of a screening phase (to ensure all participants meet all eligibility criteria to take part in the study), and an observational phase which will run for at least 6 months. Additional visits may be offered to participants where structural and functional progression of GA has not been demonstrated at the month 6 visit.
REC name
East Midlands - Leicester Central Research Ethics Committee
REC reference
25/EM/0229
Date of REC Opinion
20 Nov 2025
REC opinion
Further Information Favourable Opinion